MCID: SML008
MIFTS: 46

Small Intestine Lymphoma

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Small Intestine Lymphoma

MalaCards integrated aliases for Small Intestine Lymphoma:

Name: Small Intestine Lymphoma 38 12 15
Small Intestinal Lymphoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13996
NCIt 50 C4007
UMLS 73 C0278805

Summaries for Small Intestine Lymphoma

MalaCards based summary : Small Intestine Lymphoma, also known as small intestinal lymphoma, is related to lymphoma and tropical sprue. An important gene associated with Small Intestine Lymphoma is CD3E (CD3e Molecule), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Allograft rejection. The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include small intestine, t cells and liver, and related phenotypes are hematopoietic system and immune system

Related Diseases for Small Intestine Lymphoma

Diseases related to Small Intestine Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 lymphoma 10.6
2 tropical sprue 10.3 ALDOB CD3E
3 lymphoplasmacyte-rich meningioma 10.2 CD79A UCHL1
4 panophthalmitis 10.2 CD79A CTSL
5 immunodeficiency 18 10.1 CD3E PTPRC
6 selective igg deficiency disease 10.1 CD19 CD79A
7 hodgkin's lymphoma, lymphocytic depletion 10.1 CD79A PTPRC
8 liver inflammatory pseudotumor 10.1 PTPRC UCHL1
9 hodgkin's lymphoma, mixed cellularity 10.1 PTPRC UCHL1
10 congenital hypogammaglobulinemia 10.1 CD19 CD79A
11 posterior scleritis 10.1 CD19 CD22
12 alpha-heavy chain disease 10.1
13 immunodeficiency with hyper-igm, type 1 10.1 CD40 CD79A
14 bladder lymphoma 10.1 CD19 CD79A
15 pediatric lymphoma 10.1 CD22 CD79A MSH6
16 testicular infarct 10.1 PTPRC UCHL1
17 gastric small cell carcinoma 10.1 PTPRC UCHL1
18 alpha chain disease 10.1
19 intestinal disease 10.1
20 gnathomiasis 10.1 CD40 CTSL
21 lung lymphoma 10.0 CD19 CD22 CD79A
22 lateral medullary syndrome 10.0 CD19 CD22
23 non-gestational choriocarcinoma 10.0 B2M MSH6
24 reticulohistiocytic granuloma 10.0 PTPRC UCHL1
25 immune deficiency disease 10.0 CD19 CD40 CD79A
26 lymphoma, mucosa-associated lymphoid type 10.0 CD19 CD40 CD79A
27 renal tuberculosis 10.0 B2M CD79A CTSL
28 plasmacytoma 10.0 B2M CD79A PTPRC
29 lymphosarcoma 10.0 CD22 CD79A CTSL PTPRC
30 waldenstroem's macroglobulinemia 9.9 B2M CD19
31 solitary osseous plasmacytoma 9.9 B2M CD19 CD79A
32 non-secretory myeloma 9.9 B2M CD19 ITGAE
33 anterior scleritis 9.9 B2M CD19 CD22
34 mantle cell lymphoma 9.9 CD19 CD40 PTPRC
35 lymphoma, hodgkin, classic 9.9 CD19 CD22 CD79A PTPRC
36 common variable immunodeficiency 9.9 CD19 CD40 CD79A
37 lymphatic system cancer 9.9 CD19 CD79A PTPRC UCHL1
38 cloacogenic carcinoma 9.9 B2M PTPRC
39 gamma heavy chain disease 9.8 CBLIF CD19 PTPRC
40 intussusception 9.8
41 gastric cancer 9.8
42 inflammatory bowel disease 9.8
43 heavy chain disease 9.8
44 intestinal tuberculosis 9.8
45 plasma cell neoplasm 9.8 B2M CD19 CD79A PTPRC
46 hematologic cancer 9.8 CD19 CD22 CD7 PTPRC
47 leukemia, acute myeloid 9.7 CD19 CD22 CD7 PTPRC
48 myeloma, multiple 9.7 B2M CD19 CD40 PTPRC
49 leukocyte disease 9.7 B2M CD19 CD22 CD79A PTPRC
50 mature b-cell neoplasm 9.6 B2M CD19 CD40 CD79A PTPRC

Graphical network of the top 20 diseases related to Small Intestine Lymphoma:



Diseases related to Small Intestine Lymphoma

Symptoms & Phenotypes for Small Intestine Lymphoma

MGI Mouse Phenotypes related to Small Intestine Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 B2M CBLIF CD19 CD22 CD3E CD40
2 immune system MP:0005387 10.13 ALDOB B2M CBLIF CD19 CD22 CD3E
3 homeostasis/metabolism MP:0005376 10.07 ALDOB B2M CBLIF CD19 CD40 CD72
4 liver/biliary system MP:0005370 9.86 ALDOB B2M CBLIF CD19 CD72 CD79A
5 mortality/aging MP:0010768 9.85 ALDOB B2M CBLIF CD19 CD22 CD3E
6 neoplasm MP:0002006 9.43 B2M CD19 CD3E CD79A MSH6 PTPRC
7 renal/urinary system MP:0005367 9.1 CD19 CD40 CD72 CD79A PTPRC UCHL1

Drugs & Therapeutics for Small Intestine Lymphoma

Drugs for Small Intestine Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 1,Not Applicable
4 Orange Approved Phase 3
5
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
6
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Ondansetron Approved Phase 3 99614-02-5 4595
9
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
14
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
15
Ofloxacin Approved Phase 3 82419-36-1 4583
16
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2 93-14-1 3516
17
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
18
Morphine Approved, Investigational Phase 3 57-27-2 5288826
19 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
21 Clavulanic Acids Phase 3
22 Cytochrome P-450 Enzyme Inhibitors Phase 3
23 beta-Lactamase Inhibitors Phase 3
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antitubercular Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Amoxicillin-Potassium Clavulanate Combination Phase 3
30 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 3,Phase 2,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
34 glucocorticoids Phase 3,Phase 2,Phase 1
35 Hormones Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
37 Central Nervous System Depressants Phase 3,Phase 1
38 Adjuvants, Anesthesia Phase 3
39 Anesthetics, Intravenous Phase 3
40 Analgesics, Opioid Phase 3
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Anesthetics, General Phase 3
43 Analgesics Phase 3,Phase 1
44 Narcotics Phase 3
45 Anesthetics Phase 3
46 Autonomic Agents Phase 3,Phase 2,Phase 1
47 Antiemetics Phase 3,Phase 2,Phase 1
48 Antipsychotic Agents Phase 3
49 Serotonin Antagonists Phase 3
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
5 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
6 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
7 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
8 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
9 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
11 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
12 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
13 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
14 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
15 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
16 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
17 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
18 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
19 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
20 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
21 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
22 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
23 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
24 Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
25 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
26 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
27 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
28 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
29 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
30 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
31 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
32 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
33 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
34 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
35 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
36 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
37 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2 panobinostat
38 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
39 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
40 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
41 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
42 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00436618 Phase 2 Everolimus
43 Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Active, not recruiting NCT00416351 Phase 1, Phase 2 clofarabine
44 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
45 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
46 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2
47 Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
48 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
49 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Withdrawn NCT00621036 Phase 2 methotrexate;thiotepa
50 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma Unknown status NCT00562068 Phase 1 cyclophosphamide;doxorubicin hydrochloride;prednisolone;vincristine sulfate

Search NIH Clinical Center for Small Intestine Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Small Intestine Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Small Intestine Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Small Intestine Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Small Intestine Lymphoma

Anatomical Context for Small Intestine Lymphoma

MalaCards organs/tissues related to Small Intestine Lymphoma:

41
Small Intestine, T Cells, Liver, Bone, Colon, Lung, Monocytes

Publications for Small Intestine Lymphoma

Articles related to Small Intestine Lymphoma:

(show all 28)
# Title Authors Year
1
Identification of Mucosa-Invading and Intravascular Bacteria in Feline Small Intestinal Lymphoma. ( 27627983 )
2017
2
Diagnosis and treatment for primary small intestinal lymphoma of 59 cases: a follow-up study. ( 26728023 )
2016
3
Norwich paediatric triad: malrotation, intussusception and small intestinal lymphoma. ( 25432904 )
2014
4
Small intestinal lymphoma in a post-renal transplant patient: a rare case with late presentation. ( 23801239 )
2014
5
Laparoscopic resection of synchronous gastric cancer and primary small intestinal lymphoma: a case report. ( 24876758 )
2014
6
Clinical outcome of non-surgical treatment for primary small intestinal lymphoma diagnosed with double-balloon endoscopy. ( 22946663 )
2013
7
Ultrasonographic evaluation of the muscularis propria in cats with diffuse small intestinal lymphoma or inflammatory bowel disease. ( 20102493 )
2010
8
Primary small intestinal lymphoma presenting as a groin abscess. ( 19568563 )
2009
9
Primary small intestinal lymphoma without symptom diagnosed by colonoscopy. ( 12702058 )
2003
10
A clinicopathologic study of primary small intestine lymphoma: prognostic significance of mucosa-associated lymphoid tissue-derived lymphoma. ( 10640959 )
2000
11
Non-IPSID small intestinal lymphoma: evidence for disseminated disease at presentation. ( 7870221 )
1994
12
Primary small intestinal lymphoma. ( 1528568 )
1992
13
Double-contrast radiographic features in primary small intestinal lymphoma of the 'western' type: correlation with pathological findings. ( 1760908 )
1991
14
Combination chemotherapy for primary small intestinal lymphoma in the Middle East. ( 2472276 )
1989
15
Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. ( 3828967 )
1987
16
UCHL1 (anti-T-cell) staining pattern in small intestinal lymphoma of coeliac disease. ( 3492418 )
1986
17
Diagnostic value of upper intestinal fiber endoscopy in primary small intestinal lymphoma. A prospective study by the Tunisian-French Intestinal Lymphoma Group. ( 3756829 )
1986
18
Small intestinal lymphoma. ( 3936285 )
1985
19
Small intestinal lymphoma in three patients with acquired immune deficiency syndrome. ( 3966449 )
1985
20
Primary small intestinal lymphoma: a study of 39 cases. ( 4067738 )
1985
21
Small intestinal lymphoma. ( 4067740 )
1985
22
Right ventricular outflow tract obstruction secondary to small intestinal lymphoma. ( 7378221 )
1980
23
Strongyloides stercoralis infection and small intestinal lymphoma. ( 317839 )
1979
24
Role of bacterial overgrowth in the malabsorption syndrome of primary small intestinal lymphoma in Iran. ( 872055 )
1977
25
Small intestinal lymphoma presenting as malabsorption after vagotomy and gastrojejunostomy. ( 764843 )
1976
26
Familial lymphoma including a report of familial primary upper small intestinal lymphoma. ( 4577057 )
1973
27
Primary upper small intestinal lymphoma (so-called Mediterranean lymphoma). ( 4583015 )
1973
28
Clubbing and osteoarthropathy associated with primary upper small intestinal lymphoma. ( 5108625 )
1971

Variations for Small Intestine Lymphoma

Expression for Small Intestine Lymphoma

Search GEO for disease gene expression data for Small Intestine Lymphoma.

Pathways for Small Intestine Lymphoma

Pathways related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 B2M CD19 CD22 CD3E CD40 CD79A
2
Show member pathways
12.66 B2M CD3E CD40 CTSL PTPRC
3
Show member pathways
12.43 CD3E CD40 CD79A PTPRC
4
Show member pathways
12.39 CD19 CD22 CD79A PTPRC
5 12.39 B2M CD19 CD3E CD79A PTPRC
6
Show member pathways
12.17 CD19 CD22 CD72 CD79A PTPRC
7 12.1 B2M CD19 CD3E CD40
8
Show member pathways
12.1 CD19 CD22 CD3E CD40 PTPRC
9 11.91 CD22 CD40 PTPRC
10 11.79 B2M CD19 CD22 CD3E CD40
11 11.76 CD19 CD3E ITGAE
12
Show member pathways
11.76 B2M CD3E PTPRC
13
Show member pathways
11.74 CD19 CD22 CD79A
14 11.72 CD19 CD22 CD3E CD7
15 11.62 CD19 CD22 CD3E CD79A PTPRC
16 11.59 CD7 ITGAE PTPRC
17 11.49 CD19 CD3E ITGAE PTPRC
18 11.45 CD19 CD3E ITGAE
19 11.38 CD3E MSH6 PTPRC
20 11.1 CD40 PTPRC
21 11.08 CD19 CD22 CD3E CD40 PTPRC
22 10.59 CD19 CD3E CD40 CD79A PTPRC

GO Terms for Small Intestine Lymphoma

Cellular components related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.7 ALDOB B2M CD19 CD22 CD40 CTSL
2 plasma membrane GO:0005886 9.7 B2M CD19 CD22 CD3E CD40 CD7
3 external side of plasma membrane GO:0009897 9.17 B2M CD19 CD3E CD40 CD79A ITGAE

Biological processes related to Small Intestine Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.85 B2M CD3E CD40 CD7 CD79A
2 adaptive immune response GO:0002250 9.78 CD3E CD7 CD79A CTSL
3 B cell receptor signaling pathway GO:0050853 9.69 CD19 CD79A PTPRC
4 cell surface receptor signaling pathway GO:0007166 9.67 CD19 CD3E CD79A PTPRC
5 B cell activation GO:0042113 9.55 CD40 CD79A
6 T cell differentiation in thymus GO:0033077 9.54 B2M CD3E
7 positive regulation of T cell mediated cytotoxicity GO:0001916 9.52 B2M PTPRC
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.49 CD3E PTPRC
9 negative thymic T cell selection GO:0045060 9.43 CD3E PTPRC
10 positive thymic T cell selection GO:0045059 9.4 CD3E PTPRC
11 T cell activation GO:0042110 9.33 CD3E CD7 PTPRC
12 positive regulation of alpha-beta T cell proliferation GO:0046641 9.32 CD3E PTPRC
13 positive regulation of isotype switching to IgG isotypes GO:0048304 9.26 CD40 PTPRC
14 B cell proliferation GO:0042100 9.13 CD40 CD79A PTPRC
15 regulation of immune response GO:0050776 9.02 B2M CD19 CD22 CD3E CD40

Sources for Small Intestine Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....